Home --- News & Media --- Comunicati stampa --- Comunicati e News 2017 --- Interim Analysis of Ignyta’s Entrectinib Suggests Potential Best-in-Class Profile as a First-Line Targeted Therapy in Patients With ROS1-Positive Non-Small Cell Lung Cancer (2)

Interim Analysis of Ignyta's Entrectinib Suggests Potential Best-in-Class Profile as a First-Line Targeted Therapy in Patients With ROS1-Positive Non-Small Cell Lung Cancer (2)

San Diego, 17.10.2017

Ignyta, Inc. - Interim Analysis of Ignyta's Entrectinib Suggests Potential Best-in-Class Profile as a First-Line Targeted Therapy in Patients With ROS1-Positive Non-Small Cell Lung Cancer.

Read